NXS 3.10% $1.25 next science limited

NXS in Canncord Genuity's top 16 picks

  1. 16 Posts.
    lightbulb Created with Sketch. 2
    Next Science Limited (NXS-ASX)NXS is commercialising its Xbio technology platform to disrupt biofilm structures that are integral to myriad bacterial infections. Several product approvals and distribution agreements are in place in the US market, with several more to come in CY20, in addition to pending approvals for the European market. NXS has a unique position in addressing antibiotic resistance, with several products having blockbuster potential. We believe CY20 is an important year in the commercial development of NXS which should drive investor sentiment.
watchlist Created with Sketch. Add NXS (ASX) to my watchlist
(20min delay)
Mkt cap ! $242.7M
Open High Low Value Volume
$1.30 $1.35 $1.24 $335.9K 263.1K

Buyers (Bids)

No. Vol. Price($)
1 1647 $1.25

Sellers (Offers)

Price($) Vol. No.
$1.27 15569 1
View Market Depth
Last trade - 16.10pm 26/02/2021 (20 minute delay) ?
-0.040 ( 2.58 %)
Open High Low Volume
$1.30 $1.31 $1.24 8982
Last updated 15.56pm 26/02/2021 (live) ?
NXS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.